Polymorph of trans-dichlorotetrakis(pyridine-N)ruthenium(II) influenced by a dihydrazone: crystal structure, spectral, Hirshfeld surfaces, antimicrobial, toxicity and in silico docking studies

Basumatary, Debajani; Shankar, Madan Kumar; Byrappa, K.; Saikia, Kandarpa Kumar; Dar, Ahsana; Borah, Vedant Vikrom; Sarma, Parismita; Mahanta, P.; Asthana, Mrityunjaya; Namratha, K.

doi:10.1007/s12039-020-01829-7

Cited by 2 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solid-state form control is extremely crucial in the preparation of pharmaceutical formulation. Various solid-state forms can commonly cause a wide variation in the characteristics of the drugs, such as melting point, , solubility, − dissolution rate, morphology, − stability, , hygroscopicity, compressibility, − and toxicity. , Neglecting the solid-state forms of the drug can lead to disastrous drug deterioration which results in large economic losses and also threatens the health of patients. Capsules containing ritonavir crystal form A, manufactured by Abbott Co., Ltd., underwent crystal transformation (from ritonavir form I to ritonavir form II).…”

Section: Introductionmentioning

confidence: 99%

New Case of Pharmaceutical Solid-State Forms: Several Novel Solvates/Polymorphs of Nilotinib and Their Phase Transformation Controls

Shi

Chen

Deng

et al. 2022

Crystal Growth & Design

View full text Add to dashboard Cite

Nilotinib as a type of anticancer drug was designed for the treatment of chronic myeloid leukemia that is resistant to imatinib. Presently, very few studies of nilotinib polymorphs have been reported because of the sparing solubility of the free base compared with its salt forms. Besides, there are also hardly reports for its solvates. Notably, in this study, eight different nilotinib solid-state forms, including six new solvates (form H1, form H2a, form H2b, form H2c, form H3, and form H4) and two desolvated polymorphs (form C and form D) were initially obtained. The crystallography data of form H2a, form H2b, and form H2c were obtained using single-crystal X-ray diffraction. We found that form H2a, form H2b, and form H2c were isolated site solvates. Besides, form H1 and form H3 are suspected to be isolated site solvates based on their thermal characterizations. Furthermore, we performed antisolvent experiments and used the diffusion theory to explain the mechanism successfully. In addition, we performed a series of solventmediated phase transformation experiments of the solid-state forms specifically and studied the transformation between nilotinib solvates. To the best of our knowledge, this is the first study to report the eight new crystal forms of nilotinib. Therefore, the present study fulfills the research blank in the crystallography field of nilotinib.

show abstract

Section: Introductionmentioning

confidence: 99%

New Case of Pharmaceutical Solid-State Forms: Several Novel Solvates/Polymorphs of Nilotinib and Their Phase Transformation Controls

Shi

Chen

Deng

et al. 2022

Crystal Growth & Design

View full text Add to dashboard Cite

show abstract

“…Several tentative modes of structures have been proposed based on the spectroscopic and antimicrobial investigations of polyfunctional ligands napfhH 4, slfhH 4 , and slghH 4 and their metal complexes. One of the complex structure ruthenium complexed with pyridine (py) ligand trans-[RuCl 2 (py) 4 ] has been reported earlier (Basumatary et al, 2020). In fact, the study was intended to synthesize complexes of napfhH 4 with ruthenium and pyridine ligand in order achieve the improved absorption properties.…”

Section: Introductionmentioning

confidence: 99%

“…The ligand napfhH 4 is precipitated out during the reaction mixture. The crystallographic and biological evaluation of the structures ruthenium derivative complexed with pyridine (py) ligand trans ‐[RuCl 2 (py) 4 ] has been examined (Basumatary et al, 2020). In continuation of exploring novel ruthenium derivatives, the present authors tried to synthesize the complexes of, (a) ruthenium: bipyridine: disalicylaldehyde fumaryldihydrazone (Ru‐Bpy‐SlfhH 4 ); (b) ruthenium: bipyridine: disalicylaldehyde glutaryldihydrazone (Ru‐Bpy‐SlghH 4 ).…”

Section: Introductionmentioning

confidence: 99%

Structure‐based biological investigations on ruthenium complexes containing 2,2′‐bipyridine ligands and their applications in photodynamic therapy as a potential photosensitizer

Puttaswamy,

Mahanta,

Sarma

et al. 2023

Chem Biol Drug Des

View full text Add to dashboard Cite

Ruthenium complexes have been investigated for various biological applications by virtue of their radical scavenging, DNA binding, receptor binding, and cytotoxic abilities; especially the possible potential application of these complexes in photodynamic therapy (PDT). This study focuses on the synthesis, structural characterization and biological application (pertaining to its cytotoxicity and radical generation) of ruthenium complexed with salicylaldehyde fumaryl‐dihydrazone (slfhH4), salicylaldehyde glutaryl‐di‐hydrazone (slfgH4) and 2,2′‐bipyridine (bpy). During the synthesis, the anticipated complex was precipitated out but as serendipity, Ruthenium(II) tris (2,2′‐bipyridyl) monochloride nonahydrate {[Ru(bpy)3]2+.Cl.9H2O} (RBMN) and Ruthenium(II) tris (2,2′‐bipyridyl) monochloride septahydrate {[Ru(bpy)3]2+.Cl.7H2O}(RBMS) were crystallized from the filtrate. The crystal structure of complexes RBMN and RBMS were determined by a single‐crystal X‐ray diffraction methods and it showed that chlorine anion lies at the crystallographic axis and forms a halogen hydrogen‐bonded organic framework (XHOF) to provide the stability. In comparison with similar structures in Cambridge Crystallographic Data Center (CCDC) revealed that the nature of the XHOF framework and the layered packing are conserved. The compounds showed excellent cytotoxic ability (against L6 cells) and the nitro blue tetrazolium (NBT) assay upon irradiation to light revealed its ability to produce reactive oxygen species (ROS). The presence of partially occupied water molecules in the layered organization within the crystal packing mimics the release of ROS resulting in cytotoxicity. The structural results together with the biological data make these complexes interesting candidates for potential photosensitizers for PDT applications.

show abstract

Polymorph of trans-dichlorotetrakis(pyridine-N)ruthenium(II) influenced by a dihydrazone: crystal structure, spectral, Hirshfeld surfaces, antimicrobial, toxicity and in silico docking studies

Cited by 2 publications

References 46 publications

New Case of Pharmaceutical Solid-State Forms: Several Novel Solvates/Polymorphs of Nilotinib and Their Phase Transformation Controls

New Case of Pharmaceutical Solid-State Forms: Several Novel Solvates/Polymorphs of Nilotinib and Their Phase Transformation Controls

Structure‐based biological investigations on ruthenium complexes containing 2,2′‐bipyridine ligands and their applications in photodynamic therapy as a potential photosensitizer

Contact Info

Product

Resources

About